Breaking News

CEVEC Expands AAV Production Platform

Secures funding to expand commercialization of CAP GT-based stable adeno-associated viral (AAV) vector production platform

CEVEC Pharmaceuticals GmbH announced the successful closing of a Series D financing round with new and existing investors.    The funding will be allocated to the expansion and commercialization of CEVEC’s CAP GT-based stable adeno-associated viral (AAV) vector production platform and to the broadening of the Company’s technology portfolio.   “We are extremely encouraged and would like to thank our new and existing investors for their confidence shown in CEVEC with this finan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters